MA32729B1 - Derives d'acide 1-amino-2-cyclobutylethylboronique - Google Patents

Derives d'acide 1-amino-2-cyclobutylethylboronique

Info

Publication number
MA32729B1
MA32729B1 MA33796A MA33796A MA32729B1 MA 32729 B1 MA32729 B1 MA 32729B1 MA 33796 A MA33796 A MA 33796A MA 33796 A MA33796 A MA 33796A MA 32729 B1 MA32729 B1 MA 32729B1
Authority
MA
Morocco
Prior art keywords
amino acid
acid derivatives
relates
compositions
methods
Prior art date
Application number
MA33796A
Other languages
Arabic (ar)
English (en)
Inventor
Paul E Fleming
Jing Li
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA32729B1 publication Critical patent/MA32729B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

L'invention concerne de nouveaux composés utilisés comme inhibiteurs de protéasome. L'invention concerne également de compositions pharmaceutiques comprenant les composés de l'invention et des procédés d'utilisation de ces compositions pour traiter des maladies diverses.
MA33796A 2008-09-29 2011-04-26 Derives d'acide 1-amino-2-cyclobutylethylboronique MA32729B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19461408P 2008-09-29 2008-09-29
PCT/US2009/005324 WO2010036357A1 (fr) 2008-09-29 2009-09-25 Dérivés d’acide 1-amino-2-cyclobutylethylboronique

Publications (1)

Publication Number Publication Date
MA32729B1 true MA32729B1 (fr) 2011-10-02

Family

ID=41426361

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33796A MA32729B1 (fr) 2008-09-29 2011-04-26 Derives d'acide 1-amino-2-cyclobutylethylboronique

Country Status (25)

Country Link
US (3) US8664200B2 (fr)
EP (1) EP2346882B1 (fr)
JP (3) JP5736314B2 (fr)
KR (1) KR101739470B1 (fr)
CN (2) CN103554143B (fr)
AR (1) AR075090A1 (fr)
AU (1) AU2009297113B2 (fr)
BR (1) BRPI0919447B8 (fr)
CA (1) CA2739375C (fr)
CL (1) CL2011000653A1 (fr)
CO (1) CO6362015A2 (fr)
CR (2) CR20160475A (fr)
DO (1) DOP2011000086A (fr)
EA (1) EA030539B1 (fr)
EC (1) ECSP11011011A (fr)
IL (1) IL211983A0 (fr)
MA (1) MA32729B1 (fr)
MX (1) MX2011003317A (fr)
MY (1) MY166653A (fr)
NZ (2) NZ606001A (fr)
SG (1) SG194388A1 (fr)
TW (2) TW201024313A (fr)
UA (1) UA105503C2 (fr)
WO (1) WO2010036357A1 (fr)
ZA (1) ZA201203615B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5436860B2 (ja) 2005-11-09 2014-03-05 オニキス セラピューティクス， インク． 酵素阻害のための化合物
NZ573759A (en) 2006-06-19 2012-03-30 Proteolix Inc Peptide epoxyketones for proteasome inhibition
EA018973B1 (ru) 2007-10-04 2013-12-30 Оникс Терапьютикс, Инк. Кристаллические пептидные кето-эпоксидные ингибиторы протеаз и синтез кето-эпоксидов аминокислот
HRP20150592T4 (hr) 2008-06-17 2025-02-14 Millennium Pharmaceuticals, Inc Organoborni esterski spojevi i njihove farmaceutske kompozicije
BRPI0919668A2 (pt) 2008-10-21 2018-05-29 Onyx Therapeutics, Inc. terapia de combinação com epóxi-cetonas de peptídeo
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
EP2498793B1 (fr) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib pour l'utilsation dans la suppression des metastases
PH12012501719A1 (en) * 2010-03-01 2012-11-12 Onyx Therapeutics Inc Compounds for immunoproteasome inhibition
JP5933523B2 (ja) 2010-03-31 2016-06-08 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． １−アミノ−２−シクロプロピルエチルボロン酸の誘導体
CA2855368A1 (fr) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarqueurs de la sensibilite vis-a-vis d'inhibiteurs du proteasome
CA2855356A1 (fr) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarqueurs de la sensibilite a des inhibiteurs du proteasome
US9688702B2 (en) * 2011-12-22 2017-06-27 Ares Trading Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
CA2862492A1 (fr) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methodes de traitement du cancer
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
BR112015012909A2 (pt) * 2012-12-03 2017-07-11 Hoffmann La Roche compostos de ácido borônico de triazol substituído
CA2925935A1 (fr) 2013-10-03 2015-04-09 Millennium Pharmaceuticals, Inc. Methode de prophylaxie ou de traitement du lupus erythemateux systemique et/ou de la nephropathie lupique
WO2015106200A2 (fr) 2014-01-10 2015-07-16 Cornell University Dipeptides utilisés en tant qu'inhibiteurs des immunoprotéasomes humains
SG10202003693RA (en) 2014-05-20 2020-05-28 Millennium Pharm Inc Boron-containing proteasome inhibitors for use after primary cancer therapy
EP4180041A1 (fr) 2014-08-07 2023-05-17 Mayo Foundation for Medical Education and Research Composés et procédés pour le traitement du cancer
US11202817B2 (en) 2014-08-18 2021-12-21 Cornell University Dipeptidomimetics as inhibitors of human immunoproteasomes
ES2761774T3 (es) * 2014-10-01 2020-05-21 Merck Patent Gmbh Derivados del ácido borónico
MX2017004037A (es) * 2014-10-01 2017-07-04 Merck Patent Gmbh Derivados de acido boronico.
SG11201702623TA (en) * 2014-10-01 2017-04-27 Merck Patent Gmbh Boronic acid derivatives
WO2016050356A1 (fr) * 2014-10-01 2016-04-07 Merck Patent Gmbh Dérivés d'acide boronique
EP3362754B1 (fr) 2015-10-15 2021-12-22 Cornell University Inhibiteurs des protéasomes et leurs utilisations
WO2017222914A1 (fr) 2016-06-21 2017-12-28 Inception 4, Inc. Dérivés de prolinamide carbocycliques
EP4257191A3 (fr) 2016-06-21 2023-11-22 Orion Ophthalmology LLC Dérivés hétérocycliques de prolinamide
EP3589659B1 (fr) 2017-02-28 2025-04-09 Mayo Foundation for Medical Education and Research Combinaisons pour utilisation dans le traitement du cancer
US11203613B2 (en) 2017-10-11 2021-12-21 Cornell University Peptidomimetic proteasome inhibitors
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
ES2960987T3 (es) 2019-04-12 2024-03-07 Riboscience Llc Derivados de heteroarilo bicíclicos como inhibidores de la ectonucleótido pirofosfatasa fosfodiesterasa 1

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ203706A (en) 1982-04-22 1986-03-14 Squibb & Sons Inc Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (fr) * 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Inhibiteurs de la rénine
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5159060A (en) 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) * 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
EP0583536B1 (fr) 1992-08-14 1997-03-05 The Procter & Gamble Company Compositions détergents liquides contenant de l'acide borique
US5492900A (en) 1993-09-10 1996-02-20 Neutron Technology Corporation Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA)
US5935944A (en) 1993-09-10 1999-08-10 Neutron Technology Corporation Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA)
US6060462A (en) 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
ATE240113T1 (de) 1997-02-15 2003-05-15 Millennium Pharm Inc Behandlung von infarkten durch inhibierung von nf-kappab
EP1017398A1 (fr) 1997-09-25 2000-07-12 Proscript, Inc. INIHIBITEURS DE PROTEASOME, INHIBITEURS DES VOIES DE L'UBIQUITINE OU AGENTS ENTRAVANT L'ACTIVATION DE NF-$g(k)B PAR LES VOIES DE l'UBIQUITINE PROTEASOME POUR TRAITER DES MALADIES INFLAMMATOIRES ET DES MALADIES AUTOIMMUNES
JP2002508321A (ja) 1997-12-16 2002-03-19 セフアロン・インコーポレーテツド 抗腫瘍薬としての使用のための多触媒性プロテアーゼ阻害剤
US6169076B1 (en) 1999-03-31 2001-01-02 Glcosyn Pharmaceuticals, Inc. P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols
WO2001002601A2 (fr) 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Systemes de dosage cellulaire destines a l'examen de l'activite de la protease ns3 hcv
US6846806B2 (en) * 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
PT3078667T (pt) * 2001-01-25 2018-12-28 The United States Of America Represented By The Sec Dep Of Health And Human Services Formulação de compostos de ácido borónico
CA2446282A1 (fr) 2001-05-30 2002-12-05 Novartis Ag Derives d'acide 2-{[n-(2-amino-3-(heteroaryl ou aryl)propionyl)-aminoacyl]-amino}-alkylboronique
JPWO2003033507A1 (ja) 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
JP4412586B2 (ja) 2002-01-08 2010-02-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 エポネマイシンおよびエポキソマイシン類似物およびそれらの用途
AU2003223930A1 (en) 2002-06-14 2003-12-31 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
US20060084592A1 (en) * 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
TW200418791A (en) * 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
UA88771C2 (ru) * 2003-08-14 2009-11-25 Сефалон, Инк. Ингибиторы протеасомы и способ их применения (варианты)
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
GB0405267D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
RS53259B (sr) 2004-03-30 2014-08-29 Millennium Pharmaceuticals Inc. Sinteza bortezomiba
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
KR20080030079A (ko) 2005-07-05 2008-04-03 트러스티즈 오브 터프츠 칼리지 섬유아세포 활성 단백질 알파의 억제제
JP2009524681A (ja) 2006-01-27 2009-07-02 フェノミックス コーポレーション Ｃ型肝炎ウイルスセリンプロテアーゼインヒビターおよびそのための使用
WO2009006473A2 (fr) 2007-07-05 2009-01-08 Trustees Of Tufts College Inhibiteurs promedicaments doux de proteasome polypeptidique et methodes d'utilisation associees
EP2178888B1 (fr) 2007-08-06 2012-07-04 Millennium Pharmaceuticals, Inc. Inhibiteurs de protéasomes
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
HRP20150592T4 (hr) 2008-06-17 2025-02-14 Millennium Pharmaceuticals, Inc Organoborni esterski spojevi i njihove farmaceutske kompozicije
JP5933523B2 (ja) * 2010-03-31 2016-06-08 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． １−アミノ−２−シクロプロピルエチルボロン酸の誘導体

Also Published As

Publication number Publication date
WO2010036357A1 (fr) 2010-04-01
MY166653A (en) 2018-07-18
CR20160475A (es) 2016-12-19
CA2739375C (fr) 2019-03-12
US9771381B2 (en) 2017-09-26
CA2739375A1 (fr) 2010-04-01
JP5736314B2 (ja) 2015-06-17
BRPI0919447B1 (pt) 2021-03-30
US8664200B2 (en) 2014-03-04
IL211983A0 (en) 2011-06-30
AU2009297113A1 (en) 2010-04-01
CL2011000653A1 (es) 2011-09-30
AU2009297113B2 (en) 2016-11-10
US20170349611A1 (en) 2017-12-07
US20100081633A1 (en) 2010-04-01
US10035811B2 (en) 2018-07-31
KR101739470B1 (ko) 2017-05-24
ECSP11011011A (es) 2011-07-29
TW201024313A (en) 2010-07-01
UA105503C2 (uk) 2014-05-26
CO6362015A2 (es) 2012-01-20
MX2011003317A (es) 2011-04-26
BRPI0919447A2 (pt) 2015-12-15
SG194388A1 (en) 2013-11-29
AR075090A1 (es) 2011-03-09
CR20110216A (es) 2011-07-14
TWI598352B (zh) 2017-09-11
EA201170508A1 (ru) 2011-10-31
CN103554143B (zh) 2018-02-23
DOP2011000086A (es) 2011-04-15
TW201641504A (zh) 2016-12-01
CN102203103A (zh) 2011-09-28
ZA201203615B (en) 2015-03-25
US20140194387A1 (en) 2014-07-10
BRPI0919447B8 (pt) 2021-05-25
NZ606001A (en) 2014-08-29
EA030539B1 (ru) 2018-08-31
JP2015143264A (ja) 2015-08-06
JP2012504122A (ja) 2012-02-16
JP2017025091A (ja) 2017-02-02
EP2346882A1 (fr) 2011-07-27
EP2346882B1 (fr) 2017-09-20
KR20110082534A (ko) 2011-07-19
CN103554143A (zh) 2014-02-05
NZ592497A (en) 2013-02-22

Similar Documents

Publication Publication Date Title
MA34169B1 (fr) Dérivés d'acide 1-amino-2-cyclopropyléthylboronique
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
MA32257B1 (fr) Hydroxymethyl pyrrolidines comme agonistes des recepteurs beta-3- adrenergiques.
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA28909B1 (fr) Quinazolines utiles en tant que modulateurs de canaux ioniques
MA31167B1 (fr) Inhibiteurs de l'activite de akt
WO2007095050A3 (fr) N-hydroxyguanidines comme modulateurs de l'indolamine 2,3-dioxygénase
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
MA34767B1 (fr) Compositions et procédés pour la modulation de fxr
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA31953B1 (fr) Nouveaux derives du thiophene.
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
MA29857B1 (fr) Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
NO20076447L (no) Bicykliske derivater som modulatorer av ionekanaler
EA200802054A1 (ru) Ингибиторы фермента
NO20090979L (no) (3-amino-1,2,3,4-tetrahydro-9H-karbazol-9-yl)-eddiksyrederivater
EA200602243A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
MA29858B1 (fr) Derives de carbamoylbenzotriazole en tant qu'inhibiteurs de lipases et phospholipases